[Pharmacotherapy for aplastic anemia].

Immunosuppressive therapy for aplastic anemia in Japan has changed dramatically over the past few years. Combination with eltrombopag has been shown to improve the outcome of immunosuppressive therapy, and in the 2022 edition of the reference guide, anti-thymocyte globulin plus cyclosporine and eltrombopag became the standard treatment for severe cases. This also changed the role of immunosuppressive therapy in young patients. Further improvement in treatment results is expected now that equine-derived anti-thymocyte globulin has been approved and the indication of romiplostim has been expanded to include untreated aplastic anemia.